Instil Bio reports Q1 net loss $3.74/share; cash runway beyond 2026

Instil Bio, Inc.

2024-Q1 EPS reported -$3.74

Cash, equivalents and investments of $161.5M at March 31, 2024; runway extends beyond 2026.
Net loss per share (GAAP) $3.74 vs $8.77 YoY; non-GAAP loss per share $2.39 vs $4.29.
R&D expenses fell to $7.3M from $20.7M; restructuring/impairment charges dropped to $4.3M.
Preparing potential investigator-initiated trial of FRα-CoStAR TIL in non-small cell lung cancer.
Company is exploring in-licensing or acquiring novel therapeutic candidates for unmet needs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Instil Bio, Inc. reported the quarter ended March 31, 2024 results: EPS Net loss per share, basic and diluted were $3.74.

Period: the quarter ended March 31, 2024
EPS: Net loss per share, basic and diluted were $3.74
Result: reported results

Exact text from the filing

On May 10, 2024 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Instil Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001789769-24-000057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.